D.A. Davidson & CO. Boosts Stock Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

D.A. Davidson & CO. increased its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 36.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 11,907 shares of the medical equipment provider’s stock after acquiring an additional 3,175 shares during the period. D.A. Davidson & CO.’s holdings in Zimmer Biomet were worth $1,258,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the stock. Blue Trust Inc. boosted its position in Zimmer Biomet by 165.3% during the 3rd quarter. Blue Trust Inc. now owns 1,719 shares of the medical equipment provider’s stock valued at $187,000 after buying an additional 1,071 shares during the period. International Assets Investment Management LLC raised its stake in shares of Zimmer Biomet by 19,988.0% during the third quarter. International Assets Investment Management LLC now owns 107,471 shares of the medical equipment provider’s stock valued at $11,601,000 after acquiring an additional 106,936 shares during the last quarter. Assenagon Asset Management S.A. boosted its holdings in shares of Zimmer Biomet by 15.9% during the third quarter. Assenagon Asset Management S.A. now owns 28,145 shares of the medical equipment provider’s stock worth $3,038,000 after purchasing an additional 3,859 shares during the period. Tectonic Advisors LLC grew its stake in shares of Zimmer Biomet by 20.8% in the third quarter. Tectonic Advisors LLC now owns 3,647 shares of the medical equipment provider’s stock worth $394,000 after purchasing an additional 629 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in Zimmer Biomet by 26.2% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 17,511 shares of the medical equipment provider’s stock valued at $1,895,000 after purchasing an additional 3,633 shares during the period. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Zimmer Biomet Stock Performance

Shares of Zimmer Biomet stock opened at $104.89 on Monday. The stock has a market cap of $20.88 billion, a price-to-earnings ratio of 23.57, a PEG ratio of 1.95 and a beta of 1.02. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99. Zimmer Biomet Holdings, Inc. has a 1 year low of $97.69 and a 1 year high of $133.90. The firm’s 50-day moving average is $105.86 and its 200 day moving average is $107.46.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, beating analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same quarter in the previous year, the business earned $2.20 EPS. Sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Monday, December 30th were issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.92%. The ex-dividend date of this dividend was Monday, December 30th. Zimmer Biomet’s payout ratio is 21.57%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on ZBH. Truist Financial reiterated a “hold” rating and issued a $113.00 price objective (down from $118.00) on shares of Zimmer Biomet in a research report on Monday, February 10th. Raymond James cut their price target on shares of Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating on the stock in a report on Friday, February 7th. Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a report on Friday, February 7th. Royal Bank of Canada dropped their target price on shares of Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. Finally, Wells Fargo & Company boosted their price target on shares of Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a research report on Thursday, October 31st. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $124.15.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.